
June 23, 2025 — Serac Imaging Systems Ltd. and its clinical investigators from The Ohio State University Wexner Medical Center, U.S. and the Faculty of Medicine at the University of Malaya, Malaysia, have announced that posters featuring clinical trials directed using Seracam are being presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in New Orleans, U.S. The posters are displayed in the Science Pavilion throughout the conference and the abstracts will be published in the June supplement of the Journal of Nuclear Medicine are linked in Notes to Editors below.
Seracam is a portable hybrid gamma-optical camera for medical imaging developed by Serac Imaging Systems.
The Ohio State University poster “Intraoperative, Bedside, Intradepartmental, Small Field of View Hybrid Optical-Gamma Camera Imaging System, Seracam with Specifications and First Clinical Use in the United States” compares imaging with Seracam with standard gamma camera imaging in patients attending for routine clinical nuclear medicine imaging. Clinical applications presented include lung imaging; bone spot views; thyroid and parathyroid as well as gastric emptying where Seracam has been used for the first time.
The poster, presented by Bonnie Williams, Research Administration Management Analyst at The Ohio State University Wexner Medical Center, highlights that Seracam offers a solution for small field of view imaging without the use of larger, complex and more expensive camera systems and, in some situations, Seracam may also be suitable for larger organ imaging such as lung perfusion studies.
The poster from the University of Malaya “Seracam hybrid optical-gamma camera for intraoperative imaging in breast cancer management: Preliminary results from a prospective trial” describes a pilot study of Seracam for lymphoscintigraphy in breast cancer including the first use of Seracam for image-guided surgery in the operating room. The investigators report that the number of positive nodes detected by Seracam and the standard of care using gamma probe and blue dye were comparable.
Dr Aik Hao Ng, Principal Investigator at the University of Malaya, said, “This pilot study has demonstrated for the first time that Seracam has the potential to bring real-time high-resolution hybrid optical-gamma imaging into the operating room. We are looking forward to continuing our work with the surgical teams to expand our research in this area.”
Mark Rosser, Chief Executive of Serac Imaging Systems, added: “Seeing these results from Seracam presented at the prestigious SNMMI conference is a milestone moment for Serac Imaging Systems. We are grateful to the study teams at the Ohio State University and University of Malaya for all their work on this project. This clinical feedback is highly encouraging, and we are now looking forward to completing further clinical studies to demonstrate the clinical value of Seracam as a point-of-care solution for hybrid gamma-optical imaging.”
Seracam is for investigational use only and has not been registered or approved by the FDA, UK, European or Malaysian regulatory authorities.
For further details, please see www.seracimagingsystems.com
Abstracts published in the June supplement of the Journal of Nuclear Medicine are available here: